Wondfo CA15-3 Test Kit is a quantitative assay for measuring CA15-3 tumor marker in serum, plasma or whole blood. It supports breast cancer treatment monitoring and recurrence follow-up, helping clinics obtain timely data and reduce testing delays.

· 75 μL sample volume supports efficient assays
· 10-minute reaction time for faster reporting
· 8-1000 U/mL range supports broad measurement
· CE-marked IVD format supports lab adoption
· Finecare analyzer compatibility aids workflow

Wondfo CA19-9 Rapid Quantitative Test is a CE-marked in vitro assay for measuring CA19-9 in serum, plasma or whole blood. Using 75 uL of sample, it delivers results in 10 minutes for pancreatic cancer assessment in professional clinical laboratories.

· Broad 8–1000 U/mL measuring range
· Minimal 75 uL sample requirement
· Quantitative format supports result trending
· CE-qualified IVD product for lab workflows
· Standardized kit design simplifies operation

Wondfo CA125 Test Kit provides rapid quantitative measurement of the CA125 tumor marker in serum, plasma or whole blood. It supports ovarian cancer treatment monitoring and follow-up, helping laboratories obtain timely results for patient management.

· 75 μL sample volume reduces specimen use
· 5-700 U/mL range supports broad coverage
· 10-minute reaction time accelerates reporting
· CE-marked product supports global procurement
· Clear catalog coding supports order accuracy

Wondfo Truth-H80E HPLC Hemoglobin Analyzer is revolutionising diabetes management with cutting-edge HPLC technology that delivers lab-grade accuracy in HbA1c detection. This state-of-the-art system combines unparalleled speed with clinical precision, providing reliable HbA1c results in 60 seconds while simultaneously identifying haemoglobin variants. Its fully automated operation ensures consistent performance, making it the preferred choice for healthcare professionals seeking efficient and reliable diabetes monitoring solutions.

Wondfo Respiratory Syncytial Virus Antigen Test is an immunochromatographic assay for rapid, qualitative detection of Respiratory Syncytial Virus (RSV) antigen extracted from the nasopharyngeal swab or oropharyngeal swab specimen. The test is to be used as an aid in the diagnosis of RSV infection disease, which is caused by RSV antigen.

Wondfo Flu A&B/2019-nCoV/RSV/ADV/MP Antigen Combo Test is a qualitative screening in vitro diagnostic test designed for use by healthcare professionals. It detects six respiratory pathogen antigens: Influenza A, Influenza B, 2019 Novel Coronavirus (2019-nCoV), Respiratory Syncytial Virus (RSV), Adenovirus (ADV), and Mycoplasma Pneumoniae (MP) in human nasopharyngeal and oropharyngeal swab specimens. This user-friendly test requires no additional equipment, delivers results in 15 minutes, and is suitable for various healthcare settings. It serves as an efficient screening method, particularly valuable during flu seasons and epidemics, to aid in swift identification and potential isolation of infectious cases.